Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30195858 | 1.00 | ADORA3 (0.56) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL8047049 | 1.00 | ADORA3 (0.56) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL8371824 | 1.00 | ADORA3 (0.56) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL1319619 | 1.00 | ADORA3 (0.56) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL8368934 | 1.00 | ADORA3 (0.56) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL31265252 | 1.00 | ADORA3 (0.56) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL4215253 | 0.99 | ADORA3 (0.55) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL6305941 | 0.83 | KDM4E (0.52) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL4310230 | 0.83 | KDM4E (0.52) | ADORA3ADORA2AMAPTCDAALDH1A1 | |
| SCHEMBL11123748 | 0.83 | KDM4E (0.52) | ADORA3ADORA2AMAPTCDAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111372451-A | Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles | 斯特雷克股份有限公司 | 2020-07-03 | — | — | CN | claimed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| CN-111372451-A | Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles | 斯特雷克股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| WO-2016205566-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | disclosed |
| EP-1698635-B1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-12-14 | — | — | EP | disclosed |
| EP-2276479-A2 | PRODRUGS OF NEURAMINIDASE INHIBITORS | TSRL, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009129305-A2 | PRODRUGS OF NEURAMINIDASE INHIBITORS | TSRL, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-1482916-A4 | SCHWANN CELL AND PHOSPHODIESTERASE INHIBITORS BASED THERAPY | UNIV MIAMI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1482916-A2 | SCHWANN CELL AND PHOSPHODIESTERASE INHIBITORS BASED THERAPY | University of Miami (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003065994-A2 | SCHWANN CELL AND PHOSPHODIESTERASE INHIBITORS BASED THERAPY | UNIVERSITY OF MIAMI (US) | 2003-08-14 | — | — | WO | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1997027205-A1 | IMIDAZO[1,2-A]PYRIDINE C-NUCLEOSIDES AS ANTIVIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | ADORA3 257/4885ADORA2A 742/4885MAPT 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.